2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery

By Accumetrics Inc., PRNE
Tuesday, March 8, 2011

Management of Antiplatelet Drug Therapy Important to Quality Improvement

SAN DIEGO, March 9, 2011 - Accumetrics, Inc., a privately-held developer and marketer of the
VerifyNow(R) System, the first rapid and easy-to-use point-of-care system for
measuring platelet reactivity to multiple antiplatelet agents, announced
today that new Guidelines were recently published in The Annals of Thoracic
Surgery that include point-of-care testing for platelet reactivity as a new
recommendation for preoperative patient assessment(1).

Coronary artery bypass graft (CABG) patients on antiplatelet drugs have
an increased risk of excessive perioperative bleeding. Clopidogrel
(Plavix(R)) is often discontinued for 5-7 days before surgery to reduce this
bleeding risk. Due to the considerable variability in patient response to
clopidogrel, the Guidelines recommend point-of-care testing to "identify
clopidogrel non-responders, who are candidates for early operative coronary
revascularization and who may not require a preoperative waiting period after
clopidogrel discontinuation."

The VerifyNow P2Y12 Test allows clinicians to measure the actual level of
platelet reactivity in patients who have taken P2Y12 inhibitors (e.g. Plavix)
and who have discontinued them prior to surgery. By integrating this
information with other clinical data, clinicians are able to make more
informed decisions regarding a patient's treatment and surgery schedule in
their efforts to minimize bleeding risk and maximize patient safety.

"As the Guidelines recommend, it is very important to know which patients
are at risk of bleeding," stated Dr. Alex Zapolanski, Cardiac Surgery
Director at The Valley Heart & Vascular Institute in Ridgewood, NJ. "We use
the VerifyNow P2Y12 Test as a key piece of data to help us decide when a
patient can be taken to surgery. We have found by incorporating the test into
our practice that we have been able to reduce the average pre-surgical
patient length of stay by 3 days, resulting in significant cost savings."

"Accumetrics applauds the Society of Thoracic Surgeons and the Society of
Cardiovascular Anesthesiologists for the inclusion of point-of-care platelet
reactivity testing as a new recommendation in the Blood Conservation
Guidelines to improve outcomes and patient safety," said Timothy I. Still,
President and CEO of Accumetrics. "Cardiac surgery, interventional cardiology
and clinical cardiology are all segments in the continuum of cardiovascular
patient care where the VerifyNow System provides valuable data to healthcare

The VerifyNow System is widely used in various clinical settings where
antiplatelet medications are prescribed to reduce the occurrence of future
thrombotic events such as heart attack and stroke.

    (1) Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha
    SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD,
    Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA,
    Fitzgerald DJ, Likosky DS, Shann KG. 2011 Update to the Society of
    Thoracic Surgeons and the Society of Cardiovascular
    Anesthesiologists Blood Conservation Clinical Practice Guidelines.
    Ann Thorac Surg. 2011 Mar;91(3):944-82.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic
tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform
to help physicians determine an individual's response to multiple
antiplatelet agents. Addressing every major antiplatelet drug, including
FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel
(Effient(R)) and clopidogrel (Plavix(R))), and GP IIb/IIIa inhibitors (e.g.
ReoPro(R) and Integrilin(R)), the VerifyNow System provides valuable
information to help physicians make informed treatment decisions. For more
information about the Company and its products, visit

The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is
a registered trademark of sanofi-aventis. Effient is a registered trademark
of Eli Lilly and Company.

    Jakob Jakobsen
    Chandler Chicco Agency

    Timothy I. Still
    President and CEO

Jakob Jakobsen of Chandler Chicco Agency, +1-310-309-1003, Jjakobsen at ccapr.com, for Accumetrics; or Timothy I. Still, President and CEO of Accumetrics, +1-858-404-8260, press at accumetrics.com

will not be displayed